Peptides for Insulin Resistance: Evidence

Peptides for insulin resistance span very different levels of evidence. Semaglutide and tirzepatide sit at the established clinical end: large studies in people with obesity, prediabetes, or type 2 diabetes found improvements in glucose control and insulin-resistance markers. MOTS-c sits at the emerging end. Mouse experiments suggest effects on metabolic signaling, while human studies have mainly measured the body’s own peptide rather than tested it as a treatment. These findings do not establish that one peptide fits every patient. A physician should confirm the metabolic problem and decide whether medication, lifestyle support, or both fit the case.

Peptides for insulin resistance: the evidence gradient

The word peptide describes a molecular structure, not a shared level of clinical support. GLP-1 medicines have been tested in thousands of participants. MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA; most of its treatment evidence comes from cells and animals.

That last distinction matters. Calling MOTS-c an “exercise mimetic” describes signals seen in laboratory and animal work; it does not show that administering it substitutes for physical activity in people. The broader MOTS-c peptide evidence is useful context, but it does not move the compound into the same category as a GLP-1 medicine.

What insulin-sensitivity markers can and cannot show

Insulin sensitivity describes how effectively tissues respond to insulin. Trials often estimate it with HOMA-IR or HOMA2-IR, calculated from fasting glucose and insulin, or use more intensive clamp testing. A lower resistance index can support a biological effect, but it is not the same as a permanent outcome or a universal diagnosis.

Weight change also complicates interpretation. Losing excess weight can itself improve insulin sensitivity, so analyses try to separate weight-mediated effects from other drug effects. That is why the study population, comparator, duration, and measurement method matter more than a claim that a product “targets metabolism.”

Semaglutide has the larger clinical foundation

Semaglutide activates the GLP-1 receptor. This supports glucose-dependent insulin secretion, lowers inappropriate glucagon signaling, slows gastric emptying, and commonly reduces food intake. In a pooled analysis of STEP 1, 3, and 4, investigators assessed 3,375 adults with overweight or obesity. Among participants with prediabetes, semaglutide 2.4 mg plus lifestyle intervention was associated with greater improvements in fasting glucose, HbA1c, and HOMA-IR than placebo after 68 weeks (Perreault et al., Diabetes Care, 2022).

This was a secondary analysis of weight-management trials, not a trial of a stand-alone “insulin resistance” indication. The role of semaglutide in diagnosed diabetes is covered separately in semaglutide for type 2 diabetes. The FDA’s May 2026 Ozempic label lists the branded product for improving glycemic control in adults with type 2 diabetes, alongside diet and exercise.

Semaglutide can also be dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

Tirzepatide adds GIP receptor activity

Tirzepatide activates both GIP and GLP-1 receptors. The additional GIP component is part of its mechanism, but “dual agonist” should not be translated into a promise that it is the right choice for every person.

The 40-week SURPASS-2 trial compared tirzepatide with semaglutide in 1,879 adults with type 2 diabetes. In a post hoc biomarker analysis, HOMA2-IR fell by 15.5% to 24.0% across tirzepatide groups and by 5.1% with semaglutide 1 mg; beta-cell function markers also improved (Frias et al., Journal of Clinical Endocrinology & Metabolism, 2024). These group averages describe a trial population, not an individual forecast.

The mechanism is unpacked in how tirzepatide works. FDA’s Mounjaro trial snapshot identifies the branded tirzepatide product as a therapy for improving blood sugar control in adults with type 2 diabetes alongside diet and exercise. Tirzepatide can likewise be dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

Why MOTS-c remains at the research edge

MOTS-c is interesting because it links mitochondrial signaling to whole-body metabolism. In a 2015 Cell Metabolism experiment, researchers reported that administered MOTS-c affected metabolic homeostasis and insulin sensitivity in mice fed a high-fat diet (Lee et al., 2015). That is preclinical evidence. It can justify further study, but mouse results cannot supply a human effect size.

The human record is much narrower. A 2025 exploratory study compared circulating MOTS-c in 22 lean adults and 32 adults with obesity, then followed 10 participants after bariatric surgery. MOTS-c levels were associated with BMI and HOMA-IR, yet levels did not change after weight loss (Yoon et al., Journal of Clinical & Translational Endocrinology, 2025). The investigators measured endogenous MOTS-c; they did not administer the peptide.

MOTS-c is not FDA-approved for insulin resistance or any other condition. As of August 2026, FDA’s compounding safety summary says the agency has not identified human exposure data for drug products containing MOTS-c and lacks key information about immunogenicity and other safety risks.

Diagnosis and lifestyle remain the foundation

Insulin resistance is a metabolic state, not a symptom that identifies itself. Clinicians often interpret HbA1c, fasting glucose, blood pressure, lipids, waist measures, medications, and family history together. HOMA-IR is common in research, but there is no single universal cutoff used across routine practice. A person may instead receive a diagnosis such as prediabetes, type 2 diabetes, metabolic syndrome, or obesity that guides treatment.

Movement, nutrition, sleep, and weight management where appropriate remain first-line parts of care. Medication can support that work when a diagnosed condition and risk profile justify it. A peptide should not displace evaluation for other contributors, including sleep disorders, endocrine conditions, or medicines that affect glucose.

What a prescribing decision should separate

There are two separate questions: whether a molecule has credible evidence, and whether a particular formulation and patient are an appropriate match. Medical history, current medication, pregnancy plans, adverse-effect risk, treatment goals, and the quality of the dispensing route all affect that second answer.

At Promise, a licensed provider reviews every request, and not everyone qualifies.

For compounded GLP-1 medications, FDA says a compounded drug should be used only when a patient’s medical needs cannot be met by an approved drug. A licensed provider may still prescribe a compounded formulation when appropriate; whether to use it is a decision for the patient and prescriber. That clinical accountability is different from buying an unverified vial without a prescription.

The evidence gradient should remain visible throughout that conversation: semaglutide and tirzepatide have human trial data tied to metabolic outcomes, while MOTS-c remains an emerging research candidate without comparable human treatment evidence.